Ryght

Executive Summary

Ryght is a San Francisco-based AI startup founded in 2021 that aims to revolutionize clinical trial site selection and activation through its generative AI platform. The company's flagship product, 'AI Site Twins,' creates digital replicas of clinical research sites globally, enabling sponsors and contract research organizations (CROs) to rapidly assess site feasibility, streamline activation, and optimize patient recruitment. By leveraging machine learning and real-world data, Ryght addresses a critical bottleneck in clinical development—site selection—which traditionally relies on manual, time-consuming processes. The platform promises to reduce trial startup timelines by 30-50%, potentially saving millions in costs and accelerating drug development. With a focus on the digital health and AI sectors, Ryght is well-positioned to capture a significant share of the growing clinical trial technology market, estimated to exceed $10 billion by 2027. Ryght's value proposition is particularly compelling given the increasing complexity of global clinical trials and the push for decentralized and hybrid trial models. The company's AI-driven approach not only enhances efficiency but also improves data-driven decision-making, reducing the risk of underperforming sites. Although Ryght is still in its early stages, the demand for innovative clinical trial solutions is strong, as pharmaceutical companies and CROs seek to cut costs and speed up timelines. However, the company faces competition from established players and emerging AI startups. Key to Ryght's success will be securing strategic partnerships, demonstrating ROI with large-scale deployments, and navigating regulatory considerations for AI in healthcare. Overall, Ryght represents a promising opportunity in the intersection of AI and digital health, with the potential to disrupt a traditional industry.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round70% success
• Q4 2026Strategic Partnership with Top 10 Pharma or CRO60% success
• Q2 2026Product Launch: Enhanced Site Twin Analytics Module85% success